Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Manmeet Ahluwalia, MD, MBA; and Ashley S. Margol, MD, MS; discuss targeted therapies for adult and pediatric low-grade gliomas, pediatric diffuse midline glioma, and adult glioblastoma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Incorporate genetic and molecular information to classify gliomas and develop personalized treatment plans accurately
• Evaluate the data for recent advancements in targeted agents, immunotherapies, and other innovative treatment methods for treating patients with gliomas
• Identify strategies to integrate targeted therapies, immunotherapies, and novel emerging treatment approaches for managing pediatric patients with gliomas

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Jazz Pharmaceuticals.

Faculty:

Manmeet Ahluwalia, MD, MBA

Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Baptist Health Miami Cancer Institute
Miami, FL

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AlloVir, Apollomics, Autem Therapeutics, Bayer, Bugworks Research, Equillium, GT Medical Technologies, Incyte, Novocure, Recordati, Servier Pharmaceuticals, VBI Vaccines, Xoft; Grant/ Research Funding: Incyte, Pfizer; Ownership interests in publicly traded companies: Live AI, MimiVax, Ryght AI, TriSalus Life Sciences

Ashley S. Margol, MD, MS

Associate Professor of Clinical Pediatrics
Keck School of Medicine of the University of Southern California
Project Co-Leader, Pediatric Neuro-Oncology Consortium
Director, Brain Tumor Center and Neuro-Oncology Program
Director, Neuro-Oncology Fellowship Program
Children’s Hospital Los Angeles
Los Angeles, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Day One Biopharmaceuticals, Jazz Pharmaceuticals; Grant/Research Funding: Regeneron

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including case-based and expert panel discussion, go to https://www.gotoper.com/courses/tumor-board-clinical-integration-of-molecular-profiling-in-gliomatransforming-the-use-of-targeted-therapy-1.

Release Date

June 5, 2026

Expiration Date

June 5, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.